Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046559 | 0.82 | IDO1 (0.40) | IDO1PKMMAPTTDO2 | |
| SCHEMBL16322251 | 0.79 | PKM (0.42) | IDO1PKMMAPTTDO2 | |
| SCHEMBL16321293 | 0.77 | IDO1 (0.37) | IDO1PKMTDO2 | |
| SCHEMBL12230830 | 0.76 | IDO1 (0.39) | IDO1PKMMAPTLMNATDO2 | |
| SCHEMBL4048995 | 0.76 | KMT2A (0.41) | IDO1MAPT | |
| SCHEMBL6046615 | 0.74 | GAA (0.42) | IDO1PKMMAPTLMNATDO2 | |
| SCHEMBL19812520 | 0.74 | KMT2A (0.39) | IDO1MAPTLMNA | |
| SCHEMBL4052452 | 0.71 | PKM (0.43) | IDO1PKMMAPTLMNATDO2 | |
| SCHEMBL2517465 | 0.70 | IDO1 (0.59) | IDO1MAPTLMNATDO2 | |
| SCHEMBL16340917 | 0.69 | IDO1 (0.35) | IDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | claimed |
| EP-1879573-A4 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2009-07-08 | — | — | EP | claimed |
| EP-1879573-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006122150-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2006-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885PKM 1661/4885MAPT 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.